JAK-STAT pathway inhibitors are being explored for IBD and the JAK-STAT3 pathway inhibitor tofacitinib has been approved for treatment of UC (Salas et al., 2020), (Ducreux et al., 2014), (Bouwman et al., 2020), (Akhurst and Hata, 2012), (Huynh et al., 2019), (Mitra et al., 2020). This evidence concerns the gene SOAT1 and inflammatory bowel disease.